JP2004511518A5 - - Google Patents

Download PDF

Info

Publication number
JP2004511518A5
JP2004511518A5 JP2002535660A JP2002535660A JP2004511518A5 JP 2004511518 A5 JP2004511518 A5 JP 2004511518A5 JP 2002535660 A JP2002535660 A JP 2002535660A JP 2002535660 A JP2002535660 A JP 2002535660A JP 2004511518 A5 JP2004511518 A5 JP 2004511518A5
Authority
JP
Japan
Prior art keywords
group
alkyl
alkoxy
substituted
halogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002535660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004511518A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2001/001942 external-priority patent/WO2002032422A2/en
Publication of JP2004511518A publication Critical patent/JP2004511518A/ja
Publication of JP2004511518A5 publication Critical patent/JP2004511518A5/ja
Withdrawn legal-status Critical Current

Links

JP2002535660A 2000-10-19 2001-10-15 リウマチ様関節炎の治療のためのｅｐ４受容体インヒビター Withdrawn JP2004511518A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24182500P 2000-10-19 2000-10-19
PCT/IB2001/001942 WO2002032422A2 (en) 2000-10-19 2001-10-15 Ep4 receptor inhibitors to treat rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2004511518A JP2004511518A (ja) 2004-04-15
JP2004511518A5 true JP2004511518A5 (enExample) 2005-04-07

Family

ID=22912331

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002535660A Withdrawn JP2004511518A (ja) 2000-10-19 2001-10-15 リウマチ様関節炎の治療のためのｅｐ４受容体インヒビター
JP2002536282A Expired - Lifetime JP4060182B2 (ja) 2000-10-19 2001-10-15 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物
JP2007154590A Expired - Lifetime JP4703607B2 (ja) 2000-10-19 2007-06-11 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002536282A Expired - Lifetime JP4060182B2 (ja) 2000-10-19 2001-10-15 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物
JP2007154590A Expired - Lifetime JP4703607B2 (ja) 2000-10-19 2007-06-11 抗炎症剤及び鎮痛剤としてのアリール又はヘテロアリール縮合イミダゾール化合物

Country Status (50)

Country Link
US (4) US20020077329A1 (enExample)
EP (3) EP1326606A2 (enExample)
JP (3) JP2004511518A (enExample)
KR (2) KR20030048060A (enExample)
CN (3) CN1477960A (enExample)
AP (2) AP2001002299A0 (enExample)
AR (1) AR035498A1 (enExample)
AT (1) ATE320428T1 (enExample)
AU (3) AU2001294122A1 (enExample)
BG (2) BG107699A (enExample)
BR (2) BRPI0114704B8 (enExample)
CA (2) CA2426487A1 (enExample)
CR (2) CR6951A (enExample)
CY (1) CY1105035T1 (enExample)
CZ (2) CZ2003979A3 (enExample)
DE (1) DE60118020T2 (enExample)
DK (1) DK1326864T3 (enExample)
DO (1) DOP2001000271A (enExample)
DZ (1) DZ3513A1 (enExample)
EA (2) EA005991B1 (enExample)
EC (2) ECSP034563A (enExample)
EE (2) EE200300190A (enExample)
ES (2) ES2258554T3 (enExample)
GE (1) GEP20053673B (enExample)
GT (2) GT200100211A (enExample)
HN (1) HN2001000224A (enExample)
HR (1) HRP20030269A2 (enExample)
HU (2) HUP0303766A3 (enExample)
IL (2) IL155438A0 (enExample)
IS (2) IS6765A (enExample)
MA (2) MA26952A1 (enExample)
MX (2) MXPA03003463A (enExample)
NO (2) NO20031582L (enExample)
NZ (1) NZ525163A (enExample)
OA (2) OA12523A (enExample)
PA (1) PA8531001A1 (enExample)
PE (1) PE20020548A1 (enExample)
PL (2) PL365781A1 (enExample)
PT (1) PT1326864E (enExample)
PY (1) PY0125983A (enExample)
SI (1) SI1326864T1 (enExample)
SK (2) SK4602003A3 (enExample)
SV (1) SV2002000696A (enExample)
TN (1) TNSN01145A1 (enExample)
TW (2) TW200716100A (enExample)
UA (1) UA74391C2 (enExample)
UY (1) UY26977A1 (enExample)
WO (2) WO2002032422A2 (enExample)
YU (1) YU31303A (enExample)
ZA (2) ZA200302722B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
MXPA04009961A (es) * 2002-04-12 2004-12-13 Pfizer Compuestos de imidazol como agentes anti-inflamatorios y analgesicos.
BR0309200A (pt) * 2002-04-12 2005-02-22 Pfizer Uso de ligandos receptores ep4 no tratamento de doenças envolvidas com a il-6
JP2005532291A (ja) * 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
CA2510292A1 (en) * 2002-12-20 2004-07-15 Dynogen Pharmaceuticals, Inc. Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators
US7618914B2 (en) * 2003-02-14 2009-11-17 Wako Pure Chemical Industries, Ltd. Method for producing hydroxylamine compound using platinum catalyst fixed on ion-exchange resin
WO2004080975A1 (ja) * 2003-03-13 2004-09-23 Idemitsu Kosan Co., Ltd. 新規含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
WO2005013902A2 (en) * 2003-08-04 2005-02-17 Mayo Foundation For Medical Education And Research Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2860514A1 (fr) * 2003-10-03 2005-04-08 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
WO2005064307A2 (en) * 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
JP2007533723A (ja) * 2004-04-20 2007-11-22 ファイザー・プロダクツ・インク α２δリガンドを含む組合せ
US7271271B2 (en) * 2004-06-28 2007-09-18 Amgen Sf, Llc Imidazolo-related compounds, compositions and methods for their use
WO2006055685A2 (en) 2004-11-17 2006-05-26 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US7442716B2 (en) * 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
EP1828143B1 (en) * 2004-12-17 2013-03-20 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
AU2006221699A1 (en) * 2005-03-11 2006-09-14 Pfizer Inc. Crystal forms of an imidazole derivative
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
US20090192158A1 (en) * 2006-05-02 2009-07-30 Stacia Kargman Methods for Treating or Preventing Neoplasias
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101636385B (zh) * 2007-03-26 2012-09-05 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
DE102007037579B4 (de) 2007-08-09 2012-05-16 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
CA2698075C (en) 2007-08-27 2016-04-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
MX2011003166A (es) 2008-09-25 2011-04-27 Merck Frosst Canada Ltd Derivados de sulfonilurea beta-carbolina como antagonistas del receptor ep4.
WO2010087425A1 (ja) 2009-01-30 2010-08-05 国立大学法人京都大学 前立腺癌の進行抑制剤および進行抑制方法
CA2754702C (en) 2009-04-22 2016-06-07 Yukinori Take Selective ep4 antagonistic substance for treatment of cancer
KR101041561B1 (ko) * 2009-12-21 2011-06-15 짚라인코리아 (주) 비행용 착용복
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
SG187226A1 (en) 2010-07-28 2013-03-28 Neuralstem Inc Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2012039972A1 (en) 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
JPWO2012102254A1 (ja) * 2011-01-25 2014-06-30 キッセイ薬品工業株式会社 インドール誘導体、またはその薬理学的に許容される塩
TW201326154A (zh) * 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
US10391086B2 (en) 2013-03-19 2019-08-27 Askat Inc. Use of EP4 receptor antagonists in the treatment of cartilage disease
KR20150130404A (ko) * 2013-03-19 2015-11-23 에스크엣 인크. 연골질환 치료에서의 ep4 수용체 길항제의 용도
WO2014153280A1 (en) * 2013-03-22 2014-09-25 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
JP6484555B2 (ja) * 2013-08-29 2019-03-13 京都薬品工業株式会社 新規芳香族化合物およびその用途
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
TWI664969B (zh) 2014-03-06 2019-07-11 雅瑞塔那醫療公司 格拉匹綸(ｇｒａｐｉｐｒａｎｔ)組合物及其使用方法
CA2997692A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Crystalline forms of grapiprant
CN107148275A (zh) 2014-10-20 2017-09-08 神经干细胞公司 包含编码生长因子的外源多核苷酸的稳定的神经干细胞及其使用方法
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN105486851A (zh) * 2015-11-20 2016-04-13 中国药科大学 一种基于荧光共振能量转移技术的前列腺素受体4筛选模型
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
KR102612140B1 (ko) 2017-05-18 2023-12-08 이도르시아 파마슈티컬스 리미티드 피리미딘 유도체
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
RU2659169C1 (ru) * 2017-10-31 2018-06-28 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования риска развития иммуноопосредованных заболеваний у работающих в условиях обсеменённости воздуха рабочей зоны условно-патогенными микроорганизмами
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
US20210315909A1 (en) * 2018-07-11 2021-10-14 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
IL280051B2 (en) * 2018-07-11 2024-03-01 Arrys Therapeutics Inc EP4 inhibitors and their synthesis
LT3860998T (lt) 2018-10-05 2024-06-25 Annapurna Bio Inc. Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu
US11512088B2 (en) 2019-01-30 2022-11-29 Avista Pharma Solutions, Inc. Synthetic process and intermediates
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
WO2021027722A1 (zh) * 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
US11254675B2 (en) 2019-08-12 2022-02-22 Cadila Healthcare Limited Process for preparation of grapiprant
WO2021226162A1 (en) 2020-05-05 2021-11-11 Arrys Therapeutics, Inc. Ep4 antagonists and their use in the treatment of proliferative diseases
JP7816164B2 (ja) 2020-11-13 2026-02-18 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
CN116478155B (zh) * 2022-01-17 2025-06-13 洛阳惠中兽药有限公司 一种格拉匹伦及其中间体的制备方法
CN117800905A (zh) * 2022-09-26 2024-04-02 洛阳惠中兽药有限公司 4-(2,6-二甲基-3-硝基吡啶-4-基氨基)苯乙基氨基甲酸苄基酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8804439D0 (en) * 1988-02-25 1988-03-23 Pfizer Ltd Dihydropyridines
IL94805A (en) 1989-06-28 1994-04-12 Ciba Geigy Ag (Arylsulfonamido- and pyridyl- or imidazolyl-)-substituted carboxylic acids, processfor their preparation and pharmaceutical compositions containing them
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
GB9010404D0 (en) * 1990-05-09 1990-06-27 Pfizer Ltd Therapeutic agents
GB2330307A (en) 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
WO1999047497A2 (en) * 1998-03-13 1999-09-23 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
CA2346038A1 (en) 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
JP2000191615A (ja) * 1998-10-20 2000-07-11 Takeda Chem Ind Ltd 芳香族アミン誘導体、その製造法および剤
JP2002543067A (ja) 1999-04-22 2002-12-17 シナプティック・ファーマスーティカル・コーポレーション 選択的なｎｐｙ（ｙ５）のアンタゴニスト
HRP20010795A2 (en) 1999-04-28 2003-02-28 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives

Similar Documents

Publication Publication Date Title
EP3518975B1 (en) Formulation comprising fenfluramine and cannabidiol and its use in the treatment of seizures
KR101780666B1 (ko) Ｉｌ-23 매개 질환의 치료에서 ｅｐ4 수용체 길항제의 용도
AU2019416117A1 (en) CSF1R inhibitors for use in treating cancer
EP2275107A3 (en) Combinations for the treatment of diseases involving cell proliferation
ES2565519T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de la enfermedad cardiovascular en gatos
US9925154B2 (en) Cysteamine in the treatment of fibrotic disease
JP2014532647A5 (enExample)
KR20120089250A (ko) Ｃｋ２ 조절자로 복합 요법
EP2338516A3 (en) Multiple-variable dose regimen for treating TNF-alpha-related disorders
WO2006014381A3 (en) Use of thioflavin radiolabeled derivatives in amyloid imaging gor assessing anti-amyloid therapies
JP2006514003A5 (enExample)
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
MX2012010066A (es) Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
RU2007124492A (ru) Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы, и их фармацевтическое применение
JP2023528722A (ja) サイトカインストーム症候群及び関連疾患を治療する方法
RU2012146874A (ru) Производные пиразолопиридина
US20060241037A1 (en) Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
JP2012516353A (ja) 血液系悪性腫瘍を治療するための方法及び組成物
JP2006514013A5 (enExample)
JP2007519633A5 (enExample)
CA2476825A1 (en) Use of low molecular weight compounds for preparing a medicament useful in treating mutant p53 mediated diseases
US20080207644A1 (en) Therapeutic materials and methods
RU2010129038A (ru) Соединения, предназначенные для лечения рака
JP2000516257A5 (enExample)